Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Income from Continuing Operations (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Income from Continuing Operations for 11 consecutive years, with 8614517.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 69.32% to 8614517.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1963337.0 through Dec 2025, down 8.71% year-over-year, with the annual reading at 12163620.0 for FY2025, 13.35% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 8614517.0 at Marker Therapeutics, up from 1998662.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 8896926.0 in Q4 2023, with the low at 10906782.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 3466544.75, with a median of 4115994.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations surged 403.73% in 2023, then plummeted 88.49% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 9763316.0 in 2021, then skyrocketed by 70.0% to 2929259.0 in 2022, then soared by 403.73% to 8896926.0 in 2023, then plummeted by 42.82% to 5087615.0 in 2024, then skyrocketed by 69.32% to 8614517.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 8614517.0, 1998662.0, and 4133008.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.